Cargando…

Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)

Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen...

Descripción completa

Detalles Bibliográficos
Autores principales: Damrath, John G, Chen, Neal X, Metzger, Corinne E, Srinivasan, Shruthi, O'Neill, Kalisha, Biruete, Annabel, Avin, Keith G, Wallace, Joseph M, Allen, Matthew R, Moe, Sharon M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914155/
https://www.ncbi.nlm.nih.gov/pubmed/35309859
http://dx.doi.org/10.1002/jbm4.10600
_version_ 1784667642724876288
author Damrath, John G
Chen, Neal X
Metzger, Corinne E
Srinivasan, Shruthi
O'Neill, Kalisha
Biruete, Annabel
Avin, Keith G
Wallace, Joseph M
Allen, Matthew R
Moe, Sharon M
author_facet Damrath, John G
Chen, Neal X
Metzger, Corinne E
Srinivasan, Shruthi
O'Neill, Kalisha
Biruete, Annabel
Avin, Keith G
Wallace, Joseph M
Allen, Matthew R
Moe, Sharon M
author_sort Damrath, John G
collection PubMed
description Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen species formation and reduce parathyroid hormone (PTH) levels would have additive beneficial effects to prevent cardiovascular calcification and deleterious bone architecture and mechanics before end‐stage kidney disease. To test this hypothesis, we treated a naturally progressive model of CKD‐MBD, the Cy/+ rat, beginning early in CKD with the NADPH oxidase (NOX1/4) inhibitor GKT‐137831 (GKT), the preclinical analogue of the calcimimetic etelcalcetide, KP‐2326 (KP), and their combination. The results demonstrated that CKD animals had elevated blood urea nitrogen, PTH, fibroblast growth factor 23 (FGF23), and phosphorus. Treatment with KP reduced PTH levels compared with CKD animals, whereas GKT treatment increased C‐terminal FGF23 levels without altering intact FGF23. GKT treatment alone reduced aortic calcification and NOX4 expression but did not alter the oxidative stress marker 8‐OHdG in the serum or aorta. KP treatment reduced aortic 8‐OHdG and inhibited the ability for GKT to reduce aortic calcification. Treatments did not alter heart calcification or left ventricular mass. In the skeleton, CKD animals had reduced trabecular bone volume fraction and trabecular number with increased trabecular spacing that were not improved with either treatment. The cortical bone was not altered by CKD or by treatments at this early stage of CKD. These results suggest that GKT reduces aortic calcification while KP reduces aortic oxidative stress and reduces PTH, but the combination was not additive. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-8914155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-89141552022-03-18 Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) Damrath, John G Chen, Neal X Metzger, Corinne E Srinivasan, Shruthi O'Neill, Kalisha Biruete, Annabel Avin, Keith G Wallace, Joseph M Allen, Matthew R Moe, Sharon M JBMR Plus Original Article Chronic kidney disease‐mineral and bone disorder (CKD‐MBD) increases cardiovascular calcification and skeletal fragility in part by increasing systemic oxidative stress and disrupting mineral homeostasis through secondary hyperparathyroidism. We hypothesized that treatments to reduce reactive oxygen species formation and reduce parathyroid hormone (PTH) levels would have additive beneficial effects to prevent cardiovascular calcification and deleterious bone architecture and mechanics before end‐stage kidney disease. To test this hypothesis, we treated a naturally progressive model of CKD‐MBD, the Cy/+ rat, beginning early in CKD with the NADPH oxidase (NOX1/4) inhibitor GKT‐137831 (GKT), the preclinical analogue of the calcimimetic etelcalcetide, KP‐2326 (KP), and their combination. The results demonstrated that CKD animals had elevated blood urea nitrogen, PTH, fibroblast growth factor 23 (FGF23), and phosphorus. Treatment with KP reduced PTH levels compared with CKD animals, whereas GKT treatment increased C‐terminal FGF23 levels without altering intact FGF23. GKT treatment alone reduced aortic calcification and NOX4 expression but did not alter the oxidative stress marker 8‐OHdG in the serum or aorta. KP treatment reduced aortic 8‐OHdG and inhibited the ability for GKT to reduce aortic calcification. Treatments did not alter heart calcification or left ventricular mass. In the skeleton, CKD animals had reduced trabecular bone volume fraction and trabecular number with increased trabecular spacing that were not improved with either treatment. The cortical bone was not altered by CKD or by treatments at this early stage of CKD. These results suggest that GKT reduces aortic calcification while KP reduces aortic oxidative stress and reduces PTH, but the combination was not additive. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2022-02-11 /pmc/articles/PMC8914155/ /pubmed/35309859 http://dx.doi.org/10.1002/jbm4.10600 Text en © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Damrath, John G
Chen, Neal X
Metzger, Corinne E
Srinivasan, Shruthi
O'Neill, Kalisha
Biruete, Annabel
Avin, Keith G
Wallace, Joseph M
Allen, Matthew R
Moe, Sharon M
Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title_full Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title_fullStr Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title_full_unstemmed Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title_short Non‐Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD)
title_sort non‐additive effects of combined nox1/4 inhibition and calcimimetic treatment on a rat model of chronic kidney disease‐mineral and bone disorder (ckd‐mbd)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914155/
https://www.ncbi.nlm.nih.gov/pubmed/35309859
http://dx.doi.org/10.1002/jbm4.10600
work_keys_str_mv AT damrathjohng nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT chennealx nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT metzgercorinnee nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT srinivasanshruthi nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT oneillkalisha nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT birueteannabel nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT avinkeithg nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT wallacejosephm nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT allenmatthewr nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd
AT moesharonm nonadditiveeffectsofcombinednox14inhibitionandcalcimimetictreatmentonaratmodelofchronickidneydiseasemineralandbonedisorderckdmbd